#United States #Philadelphia #FMC Corporation #EBITDA #Q1 2026

FMC Corporation Q1 2026 Results

FMC Corporation has announced its financial results for the first quarter of 2026, presenting figures that surprisingly exceed the expectations set by market analysts. Despite experiencing a revenue decline, the company has reaffirmed its full-year outlook, indicating a confident stance moving forward.

Key Highlights of Q1 2026

In the first quarter, FMC reported a revenue of $759 million, marking a 4% decline compared to the same period in 2025. When excluding revenue from operations in India, the figure stands slightly higher at $762 million, still reflecting a 4% decrease. This drop was anticipated due to challenging market conditions, including pricing pressures and alterations in customer demand.

The organic revenue also saw a decline of 9%, which reflects the impact of various factors, including pricing adjustments to meet competitive pressures and the removal of the Indian market from the revenue considerations. Moreover, the consolidated GAAP net loss amounted to $281 million, a significant reduction of $266 million compared to Q1 of the previous year.

Adjusted EBITDA Performance

FMC's Adjusted EBITDA for Q1 2026 was recorded at $72 million, which represents a sharp decline of 40% from Q1 2025. This notable drop can be linked to lower pricing strategies and rising costs associated with raw materials and tariffs. Furthermore, the company reported an adjusted loss per diluted share of $0.23, reflecting a 41-cent decrease from the year prior.

Revenue Breakdown by Region

The revenue distribution illustrates the varied regional performances:

• - North America: $198 million (up from $186 million in Q1 2025)
• - Latin America: $177 million (down from $207 million)
• - EMEA (Europe, Middle East, and Africa): $307 million (increased from $273 million)
• - Asia (excluding India): $81 million (down from $125 million)

Excluding India, which continues to present challenges, FMC's overall revenue reflects strategic shifts and adaptations aimed at enhancing long-term viability and competitiveness.

Strategic Developments and Guidance

Looking ahead, FMC is poised to make significant strides in its operational priorities for 2026. These priorities include a targeted debt reduction of approximately $1 billion, aimed at strengthening the balance sheet and enhancing competitiveness across its core portfolio. Furthermore, the company is managing the post-patent transition for its core product, Rynaxypyr®, while simultaneously focusing on the growth of new active ingredients like Isoflex® active.

The board's ongoing examination of strategic alternatives is progressing, with multiple options under evaluation, although no commitments or agreements have been reached yet.

Full-Year Outlook Reaffirmation

Despite the challenges presented during the first quarter, FMC has reiterated its full-year financial guidance for 2026, projecting revenue to range between $3.60 billion and $3.80 billion. This represents a midpoint decline of 5% compared to 2025, primarily influenced by post-patent strategies. The adjusted EBITDA for the full year is expected to range between $670 million and $730 million, which suggests a 17% decline compared to last year.

Further, the company anticipates adjusted earnings per diluted share to range between $1.63 and $1.89, reflecting a notable reduction as they continue navigating operational challenges and market dynamics.

Conclusion

Overall, FMC Corporation's Q1 2026 results indicate a complex but optimistic trajectory, despite facing revenue declines and strategic challenges. The reaffirmation of their full-year outlook signals a commitment to overcoming obstacles and enhancing operational efficiencies as they position themselves for future growth in a changing agricultural landscape. Investors and stakeholders eagerly await further developments as the company progresses through these strategic initiatives.